Results of the SWOG S1404 phase III randomized clinical trial were recently published in JAMA Oncology. According to trial, "pembrolizumab provides superior clinical and patient-reported quality-of-life outcomes compared to standard care with adjuvant ipilimumab or high-dose interferon for high-risk resected melanoma." Conducted on 1303 patients, with a variety of genders and racial backgrounds, the SWIG S1404 trial emphasized the important of physicians discussing quality-of-life issues with patients "when making shared decisions regarding the risks and benefits of adjuvant treatment in resected melanoma."
Source mentioned: Unger JM, Darke A, Othus M, et al. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncology; Published online 23 November 2022. doi:10.1001/jamaoncol.2022.5486
No comments:
Post a Comment